Modeling and Simulation Archives

On-Demand Webinar

Evolving Regulatory Landscape for Model Informed Drug Development (MIDD): Impact of the Draft ICH M15 Guidance

SVP, PBPK Consultancy Services, Certara SVP, Quantitative Science Services, Certara Sr. Director, Clinical Pharmacology, Certara…

CertaraMay 23, 2025

Blog

CERTAINTY 2025: The power of Model-Informed Drug Development

We cover the key takeaways from CERTAINTY 2025, including the power of Model-Informed Drug Development…

CertaraMay 16, 2025

On-Demand Webinar

Explore First: How a Stepwise Approach to QTc Studies Reduces Time, Cost, and Regulatory Risk

Learn how a stepwise C-QTc approach can streamline cardiac safety evaluation, reduce costs, and align…

CertaraMay 5, 2025

Fact Sheet

Non-Animal Navigator™: Expert strategy and AI-enabled biosimulation to reduce, refine, or replace animal studies

Certara’s Non-Animal Navigator™ solution helps companies adapt by selecting and optimizing the best-fit NAM strategies.

CertaraApril 30, 2025

Announcement

Certara Announces Second Annual Certainty U.S. Event

Certara’s premier client conference explores how in-silico methods and biosimulation at scale derisk every stage…

CertaraApril 22, 2025

Blog

In case you missed it: CHI + Certara Webinar on Artificial Intelligence (AI) -Powered Model-Informed Drug Development (MIDD)

April 18, 2025 What’s next for drug development? Recapping our MIDD in the age of…

CertaraApril 18, 2025

Press Release

Certara Launches Non-Animal Navigator™ Solution to Help Drug Developers Reduce Reliance on Animal Testing

New offering provides strategic guidance and AI-enabled biosimulation to navigate FDA’s Roadmap to Reducing Animal…

CertaraApril 14, 2025

Publication

Safety of combined long-acting injectable cabotegravir and long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study

The IMPAACT 2017/MOCHA study, a phase 1/2 multicenter trial across five countries, assessed the safety,…

CertaraMarch 20, 2025

Press Coverage

How biosimulation and virtual trials can bust through clinical trial roadblocks

Discover how using biosimulation for rare disease drug development can help overcome statistical and recruitment…

CertaraMarch 14, 2025

Publication

MIDD in Japan – Implementations, challenges and opportunities

In Japan, there has been a growing adoption of Model Informed Drug Development (MIDD) approaches…

CertaraMarch 12, 2025

Modeling and Simulation